Advanced search
Publication Cover
Journal of Medical Economics Volume 25, 2022 - Issue 1
Submit an article Journal homepage
3,149
Views
3
CrossRef citations to date
0
Altmetric
Oncology

Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States

Maria Polyzoia Parexel International, Stockholm, Sweden
,
Hera Sandhub Parexel International, London, UK
,
Johan Maervoetc Parexel International, Wavre, Belgium
,
Yong Yuand Bristol Myers Squibb, Princeton, NJ, USACorrespondence[email protected]
,
Mohammad A. Chaudharyd Bristol Myers Squibb, Princeton, NJ, USA
,
Nebibe Varole Bristol Myers Squibb, Uxbridge, UK
,
Adam Leee Bristol Myers Squibb, Uxbridge, UK
,
Peter Daleb Parexel International, London, UK
,
Cheryl Jonesb Parexel International, London, UK
,
Solomon J. Lubingad Bristol Myers Squibb, Princeton, NJ, USA
&
John R. Penrodd Bristol Myers Squibb, Princeton, NJ, USA
 show all
Pages 660-668 | Received 10 Feb 2022, Accepted 28 Feb 2022, Published online: 06 Jun 2022

Related Research Data

Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States
Source: Taylor & Francis

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.